Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solanezumab in Mild Alzheimer's Disease
NCT01900665Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2013
- Primary completion
- Oct 2016
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 3 trial of solanezumab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Jul 2013; status: terminated.
02
Drugs
solanezumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01900665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01900665.